Rexulti (brexpiprazole) is not a controlled substance. It has no DEA schedule classification, which means it is not regulated under the Controlled Substances Act the way drugs like opioids, benzodiazepines, or stimulants are. Its FDA-approved label states this explicitly.
If you’re asking this question, you likely just got a prescription or are considering one, and you want to know what kind of drug you’re dealing with. Here’s what the classification means in practical terms and what you should still know about how Rexulti works in your body.
What “Not a Controlled Substance” Means for You
The DEA assigns drugs to schedules (I through V) based on their potential for abuse and dependence. Schedule II drugs like oxycodone and Adderall have the tightest restrictions: no refills allowed, prescriptions expire after six months, and pharmacies track every dispensation closely. Schedule III and IV drugs (like certain sleep aids and anti-anxiety medications) allow up to five refills within six months.
Because Rexulti falls outside all of these schedules, your prescriber can write refills without the same legal limits. You won’t face the hurdles of needing a new prescription every month or dealing with pharmacy-level tracking requirements that apply to controlled medications. That said, Rexulti still requires a prescription. It’s a powerful medication, just not one the DEA considers to have significant abuse potential.
Why Rexulti Has Low Abuse Potential
Rexulti is an atypical antipsychotic. It works by partially activating some brain receptors (particularly dopamine and serotonin receptors) while blocking others. This is a fundamentally different mechanism from the drugs that typically get scheduled. Controlled substances usually produce a rapid “reward” signal in the brain, think of the euphoria from opioids or the intense focus from stimulants. Rexulti doesn’t do that.
Its effects on dopamine receptors are relatively mild compared to drugs that flood the brain with dopamine. Brexpiprazole actually acts more as a blocker than an activator at dopamine receptors, which is essentially the opposite of what a drug of abuse does. It also strongly influences serotonin receptors and a type of adrenaline receptor, which helps reduce certain side effects like involuntary muscle movements but doesn’t create a rewarding high.
Stopping Rexulti Can Still Cause Withdrawal
The fact that Rexulti isn’t a controlled substance doesn’t mean your body won’t react if you stop taking it suddenly. Abruptly discontinuing antipsychotics can cause physical withdrawal symptoms, including nausea, vomiting, dizziness, anxiety, headache, diarrhea, sweating, restlessness, tremors, and tingling sensations. These symptoms reflect your brain readjusting to the absence of the drug, not addiction in the way most people understand it.
Clinical guidelines recommend gradually tapering off antipsychotics rather than stopping cold turkey. The risk of withdrawal is highest with abrupt discontinuation. If you’re thinking about stopping Rexulti, a slow dose reduction over weeks gives your brain time to recalibrate and minimizes these effects.
This distinction matters: physical dependence (your body adapting to a drug’s presence) is not the same as addiction (compulsive drug-seeking behavior despite harm). Many everyday medications cause withdrawal if stopped suddenly, including some blood pressure drugs and antidepressants, without being classified as controlled substances.
What Rexulti Is Prescribed For
Rexulti has three FDA-approved uses. It’s prescribed as an add-on treatment for major depressive disorder in adults when an antidepressant alone isn’t enough. It’s also approved for schizophrenia in adults and adolescents 13 and older. The newest approval, added in 2023, covers agitation associated with Alzheimer’s disease dementia.
For depression, the target dose is typically 2 mg once daily, with a maximum of 3 mg. For schizophrenia, the target is slightly higher at 2 to 4 mg daily. In all cases, treatment starts at a low dose (0.5 to 1 mg) and increases gradually over the course of one to two weeks. This slow ramp-up helps your body adjust and reduces the chance of side effects.
Important Safety Warnings
Even though Rexulti isn’t a controlled substance, it carries serious safety warnings. The FDA requires its strongest warning label (a “black box” warning) for two risks. First, antipsychotics including Rexulti are associated with increased mortality in elderly patients with dementia-related psychosis, primarily from cardiovascular events and infections like pneumonia. Second, patients with major depressive disorder, both adults and younger patients, may experience worsening depression or new suicidal thoughts, particularly early in treatment or after dose changes.
These warnings don’t mean the drug is unsafe for its approved uses, but they do mean that monitoring matters, especially in the first weeks of treatment or whenever your dose changes.